RSC4All as a machine learning nomogram to predict RSClin™ results in HR+/HER2- node-negative early breast cancer.
AuteursJacobs F, D'Amico S, Ferraro E, Agostinetto E, Tondini C, Gaudio M, Benvenuti C, Gerosa R, Saltalamacchia G, Zazzetti E, Di Rienzo R, Buonaiuto R, Martorana F, Chirco A, De Sanctis R, Della Porta MG, Santoro A, Vigneri P, Arpino MG, Giuliano M, Fornier M, de Azambuja E, Zambelli A
Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer.
AuteursLei M, Overman MJ, Yao J, André T, Lonardi S, Lenz HJ, Aglietta M, Gelsomino F, McDermott R, Wong KYM, Morse MA, Van Cutsem E, Hendlisz A, Cardin DB, Neyns B, Hill A, Krishnamurthy A, Chen F, Kochuparambil S, Jenq RR, Abdullaev S, He B, Novosiadly R, Kopetz S
Immunophenotypic changes in the tumor and tumor microenvironment during progression to multiple myeloma.
AuteursBergiers I, Köse MC, Skerget S, Malfait M, Fourneau N, Ellis JC, Vanhoof G, Smets T, Verbist B, De Maeyer D, Van Houdt J, Van der Borght K, Verona R, Heidrich B, Kurth W, Delforge M, Meuleman N, Van Droogenbroeck J, Vlummens P, Heuck CJ, Beguin Y, Bahlis N, Casneuf T, Caers J
Temporal trends and clinical determinants of urinary diversion after radical cystectomy.
AuteursPellegrino F, de Angelis M, Scilipoti P, Longoni M, Subiela JD, Contieri R, Afferi L, Zamboni S, Suardi N, Musi G, Luzzago S, D'Andrea D, Laukhtina E, Soria F, Gontero P, Del Giudice F, Fallara G, Roupret M, Grobet-Jeandin E, Baudewyns A, Tanaka H, Matsumoto S, Fujii Y, Proietti F, Simone G, Schulz GB, Pyrgidis N, Ploussard G, Antonelli A, Bertolo R, Roumiguie M, Bajeot AS, Resca S, Beatrici E, Lambert E, Mottrie A, Mir MC, Umari P, Teoh J, Wong C, Mertens LS, Pichler R, Mori K, Ślusarczyk A, Poyet C, Albisinni S, Aziz A, Volpe A, Shariat S, Pradere B, Karakiewicz P, Necchi A, Ferro M, Montorsi F, Briganti A, Moschini M
Development and International Evaluation of an Artificial Intelligence-based Model (PROGRxN-BCa) Using the World Health Organization 2004/2022 Grading System to Predict Progression Risk and Improve Substratification for Non-muscle-invasive Bladder Cancer.
AuteursKwong JCC, Al-Daqqaq Z, Chelliahpillai Y, Lee S, Kim K, Ringa M, Feifer A, Lajkosz K, Wettstein MS, Chan A, Lee T, Nguyen M, Kassouf W, Black PC, Breau RH, Lodde M, Fairey A, Lattouf JB, Jeldres C, Rendon R, Alimohamed N, Fleshner NE, Diamand R, Gontero P, Sylvester RJ, van Rhijn BWG, Kamat AM, Johnson AEW, Zlotta AR, Kulkarni GS
